Conference Track

New Agents and Insights from Basic Science

Source: CCO Independent Conference Coverage of the 2005 International AIDS Society Conference on HIV Pathogenesis and Treatment*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Interpatient Variability in CD4+ Cell Count Response in Patients With HIV Suppression Linked to T-Cell Gene Polymorphisms
NNRTI TMC120 Nontoxic and Effectively Inhibits HIV-1 Infection in Cellular and Cervical Tissue Models
HAART Plus DNA Vaccine Controls Viremia After Treatment Discontinuation in SIV-Infected Macaques
Identification of Novel Small-Molecule HIV-1 Fusion Inhibitors
Growth Hormone Therapy Improves CD4+ Cell Count in Patients on Antiretroviral Therapy With Virologic Suppression But Inadequate Immune Recovery
Use of HIV Vaccine Prior to Treatment Interruption Did Not Improve Immune Control in Patients on Initial Antiretroviral Regimen
Wide Variation in Antiretroviral Diffusion and Metabolism in Peripheral Blood and Lymph Node Mononuclear Cells
TMC114 Plus Low-Dose Ritonavir Superior to Comparator Protease Inhibitors in 3-Class-Experienced HIV Patients
Activity of D-d4FC in Antiretroviral-Experienced Patients
TMC114 Pharmacokinetics Unaltered by Concomitant Use of Ranitidine or Omeprazole
Investigational NNRTI, GW695634, Safe and Effective at Reducing HIV-1 RNA in NNRTI-Resistant Patients
Safety of TMC114/Ritonavir Comparable With Control PIs in 3-Class-Experienced HIV-Infected Patients

Expert Analysis

New Antiretroviral Agents and Insights From Basic Science

CME Program Director: John P. Phair, MD

Faculty:

Joseph J. Eron, Jr., MD
Ian M. Sanne, MBBCH, FCP(SA)
Kimberly Y. Smith, MD, MPH

Learning Objectives

Upon completion of this activity, participants should be able to:

List adverse effects associated with short-term exposure to investigational antiretrovirals in early clinical studies.
Describe recent data on the antiviral activity of investigational antiretrovirals in dose-ranging studies.
Review findings regarding the efficacy of new and investigational agents in treatment-experienced patients.

CREDIT INFORMATION

Release Date: 10/07/05

Expiration Date: 10/06/06

Physicians: maximum of 1.5 AMA PRA Category 1 Credits™

Registered Nurses: 1.8 Nursing contact hours

Pharmacists: 1.5 contact hours (0.15 CEUs)

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.